LinCART 19 CAR T therapy - Applied DNA Sciences
Alternative Names: anti-CD-19 chimeric antigen receptor T-cell therapy - Applied DNA Sciences; LinCART19; LinCART19 CAR T therapy - Applied DNA SciencesLatest Information Update: 28 Nov 2022
At a glance
- Originator iCell Gene Therapeutics
- Developer Applied DNA Sciences
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 16 Oct 2018 Preclinical trials in Haematological malignancies in USA (Parenteral)